1 active not recruiting, 1 unknown. 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Unknown 1 |
| Phase 3 | 2 | Active not recruiting 1, Unknown 1 |
Follow Hemarthrosis: new trials by email Literature Review of Hemarthrosis trials Research Report on Hemarthrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Real-World Joint Outcomes After Selective Transition to Low-Dose Emicizumab in Pediatric Hemophilia A Switching to low dose emicizumab - Hemophilia A Patient | Phase 2 / Phase 3 | Active not recruiting | Chulalongkorn University | 18 | 2025-06-01 | 2026-02-27 |
| Comparison of Outcomes Between Low Dose Emicizumab and Factor VIII in Clinically Severe Hemophilia A "Emicizumab", "HEMLIBRA®" - Severe Hemophilia A Without Inhibitor, Joint Bleed | Phase 2 / Phase 3 | Unknown | Chulalongkorn University | 15 | 2023-06-22 | 2024-03-05 |
Hemophilia A (2)
Blood Coagulation Disorders (2) · Blood Coagulation Disorders, Inherited (2) · Coagulation Protein Disorders (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Hemorrhage (2) · Hemorrhagic Disorders (2) · Joint Diseases (2) · Musculoskeletal Diseases (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2)
emicizumab (2)
Thailand (2)